Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Pheochromocytoma 2Prostatic Hyperplasia 1Paraganglioma 1Lower Urinary Tract Symptoms 1

Interventions

lutetium Lu 177 dotatate 43-Iodobenzylguanidine 4anlotinib 3gallium Ga 68 dotatate 2cabozantinib 2Temozolomide 2Sunitinib 2Phenoxybenzamine 2Magnetic Resonance Spectroscopy 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2vandetanib 1pembrolizumab 1olaparib 1lanreotide 1fluorodopa F 18 1fludarabine phosphate 1belzutifan 1atezolizumab 1Vorinostat 1Specimen Handling 1Radiosurgery 1Interleukin-13 1Genetic Testing 1Fluorodeoxyglucose F18 1Everolimus 1Erlotinib Hydrochloride 1Doxazosin 1Cyclophosphamide 1Blood Specimen Collection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Paraganglioma × Doxazosin × Clear all
NCT03176693 2023-11-20

Preoperative Alpha Blockade for Pheochromocytoma

University of California, Los Angeles

Phase 3 Completed
39 enrolled 8 charts
CNSEndocrine

Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡